Статья

A prospective randomized 14‐year follow‐up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors

Nina LindforsHelsinki University Central Hospital, Department of Orthopedic and Hand Surgery, Helsinki University, Helsinki, Finland. [email protected]Ilona KoskiTurku University Hospital and Medical Imaging Center of Southwest Finland, Turku, FinlandJouni HeikkiläThe Biomaterial Project of Turku, Department of Orthopedic and Traumatology, Turku University Hospital, Turku, FinlandKimmo MattilaTurku University Hospital and Medical Imaging Center of Southwest Finland, Turku, FinlandA. J. AhoThe Biomaterial Project of Turku, Department of Orthopedic and Traumatology, Turku University Hospital, Turku, Finland

2010en

ABI

Аннотация

A prospective randomized long-term follow-up study of bioactive glass (BG)-S53P4 and autogenous bone (AB) used as bone graft substitutes in benign bone tumor surgery during 1993-1997 was conducted. Twenty-one patients (11 in the BG group, 10 in the AB group) participated in a 14-year follow-up. X-rays and MRI scans were obtained, and in the BG group, CT scans were also performed. In the BG group, the filled cavity had a dense appearance on X-ray. MRI showed a mainly or partly fatty bone marrow, and in the large bone tumor group, remnants of glass granules were also observed. Increased cortical thickness was seen in nonossifying fibromas and enchondromas. BG-S53P4 is a safe and well-tolerated bone substitute with good long-term results. BG-S53P4 does not disturb the growth of bone in children.

Перевод пока недоступен

Идентификаторы

DOI: 10.1002/jbm.b.31636

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar